Detection of cardiac biomarkers using single polyaniline nanowire-based conductometric biosensors

Aleem M, Gao H, Eissa NG, Elghamry I, Salim SA. Recent Progress of Polymer-Based Biosensors for Cancer Diagnostic Applications: Natural versus Synthetic Polymers

Early diagnosis of cancer can significantly contribute to improving therapeutic outcomes and enhancing survival rates for cancer patients. Polymer-based biosensors have emerged as a promising tool for cancer detection due to their high sensitivity, selectivity, and low cost. These biosensors utilize functionalized polymers in different parts of the body to detect cancer biomarkers in biological samples. This approach offers several advantages over traditional detection methods, including real-time monitoring and noninvasive detection while maintaining high sensitivity and accuracy. This review discusses recent advances in the development of polymer-based biosensors for cancer detection including their design, fabrication, and performance. The essential characteristics of biosensing devices are presented, along with examples for natural and synthetic polymers commonly utilized in biosensors. Furthermore, strategies employed to tailor polymers to improve biosensing applications and future perspectives for the application of polymer-based biosensors in cancer diagnosis are also highlighted. Integrating these advancements will illuminate the potential of polymer-based biosensors as transformative tools in the early detection and management of cancer.

Therapeutic functions of medical implants from various material categories with integrated biomacromolecular systems

Medical implants are designed to replace missing parts or improve body functions and must be capable of providing structural support or therapeutic intervention for a medical condition. Advances in materials science have enabled the development of devices made from metals, polymers, bioceramics, and composites, each with its specific advantages and limitations. This review analyzes the incorporation of biopolymers, proteins, and other biomacromolecules into implants, focusing on their role in biological integration and therapeutic functions. It synthesizes advancements in surface modification, discusses biomacromolecules as carriers for controlled drug release, and explores the application of nanoceramics and composites to improve osseointegration and tissue regeneration. Biomacromolecule systems are capable of interacting with device components and therapeutic agents - such as growth factors (GFs), antibiotics, and nanoceramics - allowing control over substance release. Incorporating therapeutic agents into these systems enables localized treatments for tissue regeneration, osseointegration, post-surgery infection control, and disease and pre-existing conditions. The review highlights these materials' therapeutic advantages and customization opportunities, by covering mechanical and biological perspectives. Developing composites and hybrid drug delivery systems align with recent efforts in interdisciplinary personalized medicine and implant innovations. For instance, a trend was observed for integrating inorganic (especially nanoceramics, e.g., hydroxyapatite) and organic phases in composites for better implant interaction with biological tissues and faster recovery. This article supports understanding how integrating these materials can create more personalized, functional, durable, and biocompatible implant devices.

Electrochemical Nanosensor-Based Emerging Point-Of-Care Tools: Progress and Prospects

Early detection of disease remains a crucial challenge in medicine. Delayed diagnosis often leads to limited treatment options, increased disease progression, and unfortunately, even death in some cases. To address this, the need for rapid, cost-effective, and noninvasive diagnostic tools is paramount. In recent years, electrochemical nanosensor-based point-of-care diagnostic tools have emerged as promising tools for various fields, with significant interest in their biological and chemical applications. These tiny sensors, utilizing nanoparticles and chemical agents, can detect and monitor physical components like disease biomarkers at the nanoscale, offering a unique advantage rarely found in other diagnostic methods. This unprecedented sensitivity has made them highly sought-after tools for biological applications, particularly in disease diagnosis. This review focuses specifically on electrochemical nanosensors and their potential as diagnostic tools in medicine. We will delve into their properties, applications, current advancements, and existing limitations.

Advancements in electrochemical immunosensors towards point-of-care detection of cardiac biomarkers

Cardiovascular disease remains the leading cause of death worldwide, with mortality rates increasing annually. This underscores the urgent need for accurate diagnostic and monitoring tools. Electrochemical detection has emerged as a promising method for swiftly and precisely measuring specific biomarkers in bodily fluids. This approach is not only cost-effective and efficient compared to traditional clinical methods, but it can also be tailored to detect individual biomarkers, which makes it particularly well-suited for point-of-care (POC) applications. The ability to conduct testing at the point of care is crucial for timely interventions and personalized disease management, empowering healthcare providers to tailor treatment plans based on real-time biomarker data. Thanks to recent advancements in nanomaterials, we've seen significant progress in electrochemical detection, leading to the development of specialized rapid immunoassay systems. These systems utilize specific antibodies to target molecules, expanding the range of detectable biomarkers. This innovation has the potential to revolutionize the diagnosis and treatment of cardiovascular diseases by enhancing detection sensitivity and specificity. Ultimately, these advancements aim to improve patient outcomes by enabling earlier diagnosis, more precise monitoring, and personalized therapeutic interventions, which will contribute to more effective management of cardiovascular health globally.

Biosensors for natriuretic peptides in cardiovascular diseases. A review

Heart failure (HF) is a complex clinical syndrome associated with high rates of morbidity and mortality. Over the years, it has been crucial to find accurate biomarkers capable of doing a precise monitor of HF and provide an early diagnosis. Of these, it has been established an important role of natriuretic peptides in HF assessment. Moreover, the development of biosensors has been garnering interest as new diagnostic medical tools. In this review we first provide a general overview of HF, its pathogenesis, and diagnostic features. We then discuss the role of natriuretic peptides in heart failure by characterizing them and point out their potential as biomarkers. Finally, we adress the evolution of biosensors development and the available natriuretic peptides biosensors for disease monitoring.

Advances in Integration, Wearable Applications, and Artificial Intelligence of Biomedical Microfluidics Systems

Microfluidics attracts much attention due to its multiple advantages such as high throughput, rapid analysis, low sample volume, and high sensitivity. Microfluidics has profoundly influenced many fields including chemistry, biology, medicine, information technology, and other disciplines. However, some stumbling stones (miniaturization, integration, and intelligence) strain the development of industrialization and commercialization of microchips. The miniaturization of microfluidics means fewer samples and reagents, shorter times to results, and less footprint space consumption, enabling a high throughput and parallelism of sample analysis. Additionally, micro-size channels tend to produce laminar flow, which probably permits some creative applications that are not accessible to traditional fluid-processing platforms. The reasonable integration of biomedical/physical biosensors, semiconductor microelectronics, communications, and other cutting-edge technologies should greatly expand the applications of current microfluidic devices and help develop the next generation of lab-on-a-chip (LOC). At the same time, the evolution of artificial intelligence also gives another strong impetus to the rapid development of microfluidics. Biomedical applications based on microfluidics normally bring a large amount of complex data, so it is a big challenge for researchers and technicians to analyze those huge and complicated data accurately and quickly. To address this problem, machine learning is viewed as an indispensable and powerful tool in processing the data collected from micro-devices. In this review, we mainly focus on discussing the integration, miniaturization, portability, and intelligence of microfluidics technology.

New diagnostic and therapeutic strategies for myocardial infarction via nanomaterials

Myocardial infarction is lethal to patients because of insufficient blood perfusion to vital organs. Several attempts have been made to improve its prognosis, among which nanomaterial research offers an opportunity to address this problem at the molecular level and has the potential to improve disease prevention, diagnosis, and treatment significantly. Up to now, nanomaterial-based technology has played a crucial role in broad novel diagnostic and therapeutic strategies for cardiac repair. This review summarizes various nanomaterial applications in myocardial infarction from multiple aspects, including high precision detection, pro-angiogenesis, regulating immune homeostasis, and miRNA and stem cell delivery vehicles. We also propose promising research hotspots that have not been reported much yet, such as conjugating pro-angiogenetic elements with nanoparticles to construct drug carriers, developing nanodrugs targeting other immune cells except for macrophages in the infarcted myocardium or the remote region. Though most of those strategies are preclinical and lack clinical trials, there is tremendous potential for their further applications in the future.

Recent advances in the utilization of polyaniline in protein detection: a short review

Attachment of biomolecules to polyaniline.

Troponin I as a Biomarker for Early Detection of Acute Myocardial Infarction

Acute myocardial infarction (AMI) as the main cause of death among cardiovascular diseases is defined as a deficiency of oxygen that generates irreversible tissue necrosis in the heart muscle. For diagnostic measurements, the evaluation of cardiac markers concentration like cardiac triponin I (cTnI) in plasma or saliva thought the use of biosensors has become one of the most commonly applied strategies for prognosis of AMI. Inside this diagnostic devices, electrochemical (ECL) ones have been highly encourage to improve sensing capabilities by using different materials and configurations. In this review, the authors presents a summary of studies that involves cTnI detection using ECL biosensors modified with nanomaterials and related mechanisms.

Nanowire-based sensor electronics for chemical and biological applications

Detection and recognition of chemical and biological species via sensor electronics are important not only for various sensing applications but also for fundamental scientific understanding. In the past two decades, sensor devices using one-dimensional (1D) nanowires have emerged as promising and powerful platforms for electrical detection of chemical species and biologically relevant molecules due to their superior sensing performance, long-term stability, and ultra-low power consumption. This paper presents a comprehensive overview of the recent progress and achievements in 1D nanowire synthesis, working principles of nanowire-based sensors, and the applications of nanowire-based sensor electronics in chemical and biological analytes detection and recognition. In addition, some critical issues that hinder the practical applications of 1D nanowire-based sensor electronics, including device reproducibility and selectivity, stability, and power consumption, will be highlighted. Finally, challenges, perspectives, and opportunities for developing advanced and innovative nanowire-based sensor electronics in chemical and biological applications are featured.

A review of biosensors for the detection of B-type natriuretic peptide as an important cardiovascular biomarker

Heart disease, as the most serious threat to human health globally, is responsible for rising mortality rates, largely due to lifestyle and diet. Unfortunately, the main problem for patients at high risk of heart disease is the validation of prognostic tests. To this end, the detection of cardiovascular biomarkers has been employed to obtain pathological and physiological information in order to improve prognosis and early-stage diagnosis of chronic heart failure. Short-term changes in B-type natriuretic peptide are known as a standard and important biomarker for diagnosis of heart failure. The most important problem for detection is low concentration and short half-life in the blood. The normal concentration of BNP in blood is less than 7 nM (25 pg/mL), which increases significantly to more than 80 pg/mL. Therefore, the development of new biosensors with better sensitivity, detection limit, and dynamic range than current commercial kits is urgently needed. This review classifies the biosensors designed for detection of BNP into electrochemical, optical, microfluidic, and lateral-flow immunoassay techniques. The review clearly demonstrates that a variety of immunoassay, aptasensor, enzymatic and catalytic nanomaterials, and fluorophores have been successfully employed for detection of BNP at low attomolar ranges. Dtection of B-type natriuretic peptide with biosensors.

Induced bioresistance via BNP detection for machine learning-based risk assessment

Machine Learning (ML) is a powerful tool for big data analysis that shows substantial potential in the field of healthcare. Individual patient data can be inundative, but its value can be extracted by ML's predictive power and ability to find trends. A great area of interest is early diagnosis and disease management strategies for cardiovascular disease (CVD), the leading cause of death in the world. Treatment is often inhibited by analysis delays, but rapid testing and determination can help improve frequency for real time monitoring. In this research, an ML algorithm was developed in conjunction with a flexible BNP sensor to create a quick diagnostic tool. The sensor was fabricated as an ion-selective field effect transistor (ISFET) in order to be able to quickly gather large amounts of electrical data from a sample. Artifical samples were tested to characterize the sensors using linear sweep voltammetry, and the resulting data was utilized as the initial training set for the ML algorithm, an implementation of quadratic discriminant analysis (QDA) written in MATLAB. Human blood serum samples from 30 University of Pittsburgh Medical Center (UPMC) patients were tested to evaluate the effective sorting power of the algorithm, yielding 95% power in addition to ultra fast data collection and determination.

Label-free anti-Müllerian hormone sensor based on polyaniline micellar modified electrode

A label-free electrochemical immunosensor based on polyaniline (PANI) micellar electrode was firstly fabricated for direct AMH detection. To control the size regularity of PANI, a micelle-based method using ammonium peroxydisulfate (APS) as a reducing agent was employed in the polymerization process. The Anti-AMH antibodies were readily immobilized onto PANI via peptide bond to enhance the sensor specificity and sensitivity. This sensor was applied for the detection of AMH, an ovarian response indicator in female related to residual eggs during a woman's monthly cycle. The sensor performances were systematically investigated by differential pulse voltammetry. The anodic peak current decreases with the increase of AMH concentration owing to blocking of electron transfer by AMH. Under the optimal conditions, this sensor offers high sensitivity with a low detection limit of 0.1 ng mL^-1 and a wide linear range of 0.1-4 ng mL^-1, which is sensitive enough to indicate the ability to produce eggs during a woman's monthly cycle. Furthermore, this system requires lower sample volume (5 μL), while offers the simple fabrication with low cost and no synthetic challenge and faster analysis compared with a standard ELISA. Ultimately, this sensor was successfully applied for the detection of AMH in human serum with satisfactory results. Thus, it might be an alternative tool for AMH screening in clinical setting.

Acute Myocardial Infarction Biosensor: A Review From Bottom Up

Acute myocardial infarction (AMI) is a cardiovascular disease that is produced due to a deficiency of oxygen generating irreversible damage in the heart muscle. In diagnosis, electrocardiogram (ECG) investigation has been the main method but is insufficient, so approaches like the measurement of biomarkers levels in plasma or saliva have become one of the most commonly applied strategies for prognosis of AMI, as some of them are specifically related to a heart attack. Many tests are carrying on to determine biological markers changes, but usually, they present disadvantages related to time consumption and laborious work. To overcome the issues, researchers around the world have been developing different ways to enhance detection through the use of biosensors. These diagnostic devices have a biological sensing element associated to a physicochemical transducer that can be made from different materials and configurations giving place to different kinds of detection: Electrical/Electrochemical, Optical and Mechanical. In this review, the authors presents relevant investigations related to the most important biomarkers and biosensors used for their detection having in mind the nanotechnology participation in the process through the application of nanostructures as a good choice for device configuration.

Smart diagnostics devices through artificial intelligence and mechanobiological approaches

The present work illustrates the promising intervention of smart diagnostics devices through artificial intelligence (AI) and mechanobiological approaches in health care practices. The artificial intelligence and mechanobiological approaches in diagnostics widen the scope for point of care techniques for the timely revealing of diseases by understanding the biomechanical properties of the tissue of interest. Smart diagnostic device senses the physical parameters due to change in mechanical, biological, and luidic properties of the cells and to control these changes, supply the necessary drugs immediately using AI techniques. The latest techniques like sweat diagnostics to measure the overall health, Photoplethysmography (PPG) for real-time monitoring of pulse waveform by capturing the reflected signal due to blood pulsation), Micro-electromechanical systems (MEMS) and Nano-electromechanical systems (NEMS) smart devices to detect disease at its early stage, lab-on-chip and organ-on-chip technologies, Ambulatory Circadian Monitoring device (ACM), a wrist-worn device for Parkinson's disease have been discussed. The recent and futuristic smart diagnostics tool/techniques like emotion recognition by applying machine learning algorithms, atomic force microscopy that measures the fibrinogen and erythrocytes binding force, smartphone-based retinal image analyser system, image-based computational modeling for various neurological disorders, cardiovascular diseases, tuberculosis, predicting and preventing of Zika virus, optimal drugs and doses for HIV using AI, etc. have been reviewed. The objective of this review is to examine smart diagnostics devices based on artificial intelligence and mechanobiological approaches, with their medical applications in healthcare. This review determines that smart diagnostics devices have potential applications in healthcare, but more research work will be essential for prospective accomplishments of this technology.

Pyridinium porphyrins and AuNPs mediated bionetworks as SPR signal amplification tags for the ultrasensitive assay of brain natriuretic peptide

Extension of the self-assembled bionanonetworks into surface plasmon resonance (SPR) assay investigation provides an effective signal amplification approach. We fabricated a bionetwork by nucleic acids, organic compounds, and supramolecular gold nanoparticles for ultrasensitive SPR detection of B-type natriuretic peptide (BNP). The SPR method was developed by a sandwich-type format of aptamer-target-antibody, and the aptamer-modified bionanonetworks induced localized SPR and large refractive index for different concentrations of the target BNP. The linear concentration range and limit of detection were 1-10,000 pg/mL (R² = 0.9852) and 0.3 pg/mL respectively. The detection recovery was in the range 92.13 to 108.69%. The approach embraces the following main advantages: (1) Cooperative double recognition was realized by calix[4]arenes for amino aptamers and pyridinium porphyrins. (2) The approach provided the specificity for supramolecular-based nanomaterials and a simple synthesis process via the ordered self-assembly under mild conditions. (3) The bionanonetworks endowed the SPR assay with signal amplification and stable determination for trace proteins. Therefore, it is expected that this study may offer a new SPR signal-amplified platform of organic-inorganic bionanonetworks to achieve sensitive, stable, and real-time determination. Graphical abstract Schematic of bionanonetwork based on porphyrin-mediated functionalized gold nanoparticles for SPR signal amplification to quantitatively detect BNP.

Magnetic gold nanocomposite and aptamer assisted triple recognition electrochemical immunoassay for determination of brain natriuretic peptide

A triple recognition voltammetric method for the determination of brain natriuretic peptide (BNP) is described. Gold nanoparticles (AuNPs) and magnetic nanoparticles (MagNPs), sized 26 and 310 nm, respectively, were synthesized and characterized by transmission electron microscopy (TEM), FT-IR, dynamic light scattering (DLS), and Z-potential measurements. Antibody-modified MagNPs and methylene blue-labeled aptamer (Apt-MB)-modified AuNPs were used as an identifier, a signal reporter, and an amplifier, respectively. In the presence of BNP, the magnetic gold nanocomposite is formed through cascade conjugation via specific interaction. It then hybridized with complementary DNA (cDNA) on the interface, thereby amplifying the current signal of Apt-MB and increasing the selectivity of the immunoassay. Results obtained demonstrate the development of a highly selective method with a detection limit of 0.56 pg mL^-1 and a linear response over the concentration range 1-10,000 pg mL^-1. The standard deviation of the method is < 6% while the recovery ranged from 92.2 to 104.2%. Graphical abstract Schematic representation of triple recognition electrochemical immunosensor based on two functionalized nanoparticles (antibody-modified magnetic nanoparticle (MNP-Ab) and aptamer-modified gold nanoparticle (AuNPs-Apt)) for determination of brain natriuretic peptide (BNP).

Biomimetic nanoparticle technology for cardiovascular disease detection and treatment

Cardiovascular disease (CVD), which encompasses a number of conditions that can affect the heart and blood vessels, presents a major challenge for modern-day healthcare. Nearly one in three people has some form of CVD, with many suffering from multiple or intertwined conditions that can ultimately lead to traumatic events such as a heart attack or stroke. While the knowledge obtained in the past century regarding the cardiovascular system has paved the way for the development of life-prolonging drugs and treatment modalities, CVD remains one of the leading causes of death in developed countries. More recently, researchers have explored the application of nanotechnology to improve upon current clinical paradigms for the management of CVD. Nanoscale delivery systems have many advantages, including the ability to target diseased sites, improve drug bioavailability, and carry various functional payloads. In this review, we cover the different ways in which nanoparticle technology can be applied towards CVD diagnostics and treatments. The development of novel biomimetic platforms with enhanced functionalities is discussed in detail.

A label-free aptasensor FET based on Au nanoparticle decorated Co3O4 nanorods and a SWCNT layer for detection of cardiac troponin T protein

Acute myocardial infarction (AMI) is a serious health problem that must be identified in its early stages. Considerable progress has been made in understanding the condition of AMI through ascertaining the role of biomarkers, such as myoglobin, cardiac troponin proteins (T and I), creatine kinase-MB, and fatty acid-binding protein (FABP). A field-effect transistor (FET) is an effective platform; however, innovations are required in all layers of the FET for it to become robust and highly sensitive. For the first time, we made use of the synergistic combination of noble metal nanoparticles (AuNPs) with Co₃O₄ for the detection of cardiac troponin T (cTnT) in a FET platform. We determined the morphology of Au-decorated Co₃O₄ NRs and their electronic properties by characterizing the channel layer using electron microscopies and transient measurements. Subsequently, we performed the detection of cardiac troponin T by immobilizing its complementary biotinylated DNA aptamer on the channel surface using a drop-casting method. To understand the changes in drain current caused by this interaction, we probed our SWCNT-Co₃O₄ NR transistor with limited gate and drain bias (≤1 V), achieving a sensitivity of 0.5 μA μg^-1 mL^-1 for the Au-decorated NRs. A 250% increase in the sensitivity and a limit of detection (LOD) of 0.1 μg mL^-1 were achieved by using this device. Finally, selectivity studies proved that this synergistic combination works well in the FET configuration for the successful detection of cTnT.

Towards Point-of-Care Heart Failure Diagnostic Platforms: BNP and NT-proBNP Biosensors

Heart failure is a class of cardiovascular diseases that remains the number one cause of death worldwide with a substantial economic burden of around $18 billion incurred by the healthcare sector in 2017 due to heart failure hospitalization and disease management. Although several laboratory tests have been used for early detection of heart failure, these traditional diagnostic methods still fail to effectively guide clinical decisions, prognosis, and therapy in a timely and cost-effective manner. Recent advances in the design and development of biosensors coupled with the discovery of new clinically relevant cardiac biomarkers are paving the way for breakthroughs in heart failure management. Natriuretic neurohormone peptides, B-type natriuretic peptide (BNP) and N-terminal prohormone of BNP (NT-proBNP), are among the most promising biomarkers for clinical use. Remarkably, they result in an increased diagnostic accuracy of around 80% owing to the strong correlation between their circulating concentrations and different heart failure events. The latter has encouraged research towards developing and optimizing BNP biosensors for rapid and highly sensitive detection in the scope of point-of-care testing. This review sheds light on the advances in BNP and NT-proBNP sensing technologies for point-of-care (POC) applications and highlights the challenges of potential integration of these technologies in the clinic. Optical and electrochemical immunosensors are currently used for BNP sensing. The performance metrics of these biosensors-expressed in terms of sensitivity, selectivity, reproducibility, and other criteria-are compared to those of traditional diagnostic techniques, and the clinical applicability of these biosensors is assessed for their potential integration in point-of-care diagnostic platforms.

Nanoscale Technologies for Prevention and Treatment of Heart Failure: Challenges and Opportunities

The adult myocardium has a limited regenerative capacity following heart injury, and the lost cells are primarily replaced by fibrotic scar tissue. Suboptimal efficiency of current clinical therapies to resurrect the infarcted heart results in injured heart enlargement and remodeling to maintain its physiological functions. These remodeling processes ultimately leads to ischemic cardiomyopathy and heart failure (HF). Recent therapeutic approaches (e.g., regenerative and nanomedicine) have shown promise to prevent HF postmyocardial infarction in animal models. However, these preclinical, clinical, and technological advancements have yet to yield substantial enhancements in the survival rate and quality of life of patients with severe ischemic injuries. This could be attributed largely to the considerable gap in knowledge between clinicians and nanobioengineers. Development of highly effective cardiac regenerative therapies requires connecting and coordinating multiple fields, including cardiology, cellular and molecular biology, biochemistry and chemistry, and mechanical and materials sciences, among others. This review is particularly intended to bridge the knowledge gap between cardiologists and regenerative nanomedicine experts. Establishing this multidisciplinary knowledge base may help pave the way for developing novel, safer, and more effective approaches that will enable the medical community to reduce morbidity and mortality in HF patients.

Multifunctional one-dimensional polymeric nanostructures for drug delivery and biosensor applications

Advances in nanotechnology in the last decades have paved the way for significant achievements in diagnosis and treatment of various diseases. Different types of functional nanostructures have been explored and utilized as tools for addressing the challenges in detection or treatment of diseases. In particular, one-dimensional nanostructures hold great promise in theranostic applications due to their increased surface area-to-volume ratios, which allow better targeting, increased loading capacity and improved sensitivity to biomolecules. Stable polymeric nanostructures that are stimuli-responsive, biocompatible and biodegradable are especially preferred for bioapplications. In this review, different synthesis techniques of polymeric one-dimensional nanostructures are explored and functionalization methods of these nanostructures for specific applications are explained. Biosensing and drug delibiovery applications of these nanostructures are presented in detail.

Electrochemical cardiovascular platforms: Current state of the art and beyond

Cardiovascular diseases (CVD) remain the leading cause of death within industrialized nations as well as an increasing cause of mortality and morbidity in many developing countries. Smoking, alcohol consumption and increased level of blood cholesterol are the main CVD risk factors. Other factors, such as the prevalence of overweight/obesity and diabetes, have increased considerably in recent decades and are indirect causes of CVD. Among CVDs, the acute coronary syndrome (ACS) represents the most common cause of emergency hospital admission. Since the prognosis of ACS is directly associated with timely initiation of revascularization, missed, misdiagnosis or late diagnosis have unfavorable medical implications. Early ACS diagnosis can reduce complications and risk of recurrence, finally decreasing the economic burden posed on the health care system as a whole. To decrease the risk of ACS and related CVDs and to reduce associated costs to healthcare systems, a fast management of patients with chest pain has become crucial and urgent. Despite great efforts, biochemical diagnostic approaches of CVDs remain difficult and controversial medical challenges as cardiac biomarkers should be rapidly released into the blood at the time of ischemia and persistent for a sufficient length of time to allow diagnostics, with tests that should be rapid, easy to perform and relatively inexpensive. Early biomarker assessments have involved testing for the total enzyme activity of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and creatine kinase (CK), which cardiac troponins being the main accepted biomarkers for diagnosing myocardial injury and acute myocardial infarction (AMI). To allow rapid diagnosis, it is necessary to replace the traditional biochemical assays by cardiac biosensor platforms. Among the numerous of possibilities existing today, electrochemical biosensors are important players as they have many of the required characteristics for point-of-care tests. Electrochemical based cardiac biosensors are highly adapted for monitoring the onset and progress of cardiovascular diseases in a fast and accurate manner, while being cheap and scalable devices. This review outlines the state of the art in the development of cardiac electrochemical sensors for the detection of different cardiac biomarkers ranging from troponin to BNP, N-terminal proBNP, and others.

Simultaneous detection of three biomarkers related to acute myocardial infarction based on immunosensing biochip

An immunosensing biochip for simultaneous detection of three biomarkers related to acute myocardial infarction (AMI) was developed based on anionic soybean peroxidase (SBP) functionalized nanoprobe and chemiluminescent imaging. The nanoprobes (Ab2-SiO₂-SBP) were fabricated by co-immobilization of SBP and one of the detection polyclonal antibodies, anti-cardiac troponin I antigen (anti-cTnI), anti-creatine kinase-MB (anti-CK-MB) and anti-myoglobin (anti-Myo), on the silica nanoparticle surface. The detection sensitivity was enhanced since the large surface area of silica carriers increased the loading of SBP for per sandwiched immunoreaction. The immunosensing biochip designed as 3 × 8 wells array was constructed by simultaneously immobilizing three capture monoclonal antibodies on the same one microtiter well with 2 × 3 active spots. In the presence of target protein, the nanoprobes will be attached onto the spots with high specificity through the sandwiched immunoreactions, which triggered the chemiluminescence (CL) signals on each sensing site of the microtiter plates and allowed to CL imaging of three biomarkers in one well at the same time. Therefore, the proposed biochip was a promising convenient strategy for simultaneous detection of cTnI, CK-MB and Myo, which showed potential application for multianalyte determination in clinical diagnostics.

Top-down and sensitive indium oxide nanoribbon field effect transistor biosensor chips integrated with on-chip gate electrodes toward point of care applications

We report a scalable, uniform, and sensitive top-down fabricated indium oxide (In₂O₃) nanoribbon biosensor platform with integrated on-chip gate electrodes using two photolithographic masks. The purpose of this on-chip gate electrode is to control the operational point of the sensor during biomolecular detection replacing the cumbersome external Ag/AgCl electrode. It exhibits excellent capability in gating transistors in an aqueous condition and high stability during the sensing experiment, which is similar to the Ag/AgCl electrode. Its compactness increases the portability and pushes this platform toward a practical use. To demonstrate its capability for detection of biomolecules, we combine this platform with the electronic enzyme-linked immunosorbent assay (ELISA) technique to amplify the signal and to bypass limitation of the Debye screening effect from high salt concentration of physiological samples. Troponin I, a cardiac marker for diagnosis of acute myocardial infarction (AMI), was selected as the target molecule in this study. The In₂O₃ nanoribbon device offers a high response of 30% toward 0.1 pg ml^-1 troponin I concentration and a lower detection limit than that of the commercial ELISA kit on the market by five orders of magnitude. The total assay time from the sample collection to the data acquisition is about 45 min, which is within the constraint of the emergency care application. With the demonstrated sensitivity, uniformity, scalability, quick turn-around time and ability to be integrated, our In₂O₃ nanoribbon biosensor platform has high potential toward clinical tests for early diagnosis of AMI.

Futuristic biosensors for cardiac health care: an artificial intelligence approach

Biosensor-based devices are pioneering in the modern biomedical applications and will be the future of cardiac health care. The coupling of artificial intelligence (AI) for cardiac monitoring-based biosensors for the point of care (POC) diagnostics is prominently reviewed here. This review deciphers the most significant machine-learning algorithms for the futuristic biosensors along with the internet of things, computational techniques and microchip-based essential cardiac biomarkers for real-time health monitoring and improving patient compliance. The present review also discusses the recently developed cardiac biosensors along with technical strategies involved in their mechanism of working and their applications in healthcare. Additionally, it provides a key for the ontogeny of an effective and supportive hierarchical protocol for clinical decision-making about personalized medicine through combinatory information analysis, and integrated multidisciplinary AI approaches.

A review on B-type natriuretic peptide monitoring: assays and biosensors

Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a powerful cardiovascular biomarker for a number of disease states, specifically heart failure. Concurrent with such a discovery, much effort has been allocated to the precise monitoring of physiological BNP levels. Thus, it can be used to guide the therapy of heart failure and determine the patient's stage of disease. Thus, we discuss in this article BNP as a potent biomarker. Subsequently, we will review the progress of biosensing devices as they could be applied to monitor BNP levels as assays, benchtop biosensors and implantable biosensors. The analytical characteristics of commercially available BNP assays are presented. Still emerging as a field, we define four obstacles that present opportunity for the future development of implantable biosensor: foreign body response, sensor renewability, sensitivity and selectivity.

Organ-On-A-Chip Platforms: A Convergence of Advanced Materials, Cells, and Microscale Technologies

Significant advances in biomaterials, stem cell biology, and microscale technologies have enabled the fabrication of biologically relevant tissues and organs. Such tissues and organs, referred to as organ-on-a-chip (OOC) platforms, have emerged as a powerful tool in tissue analysis and disease modeling for biological and pharmacological applications. A variety of biomaterials are used in tissue fabrication providing multiple biological, structural, and mechanical cues in the regulation of cell behavior and tissue morphogenesis. Cells derived from humans enable the fabrication of personalized OOC platforms. Microscale technologies are specifically helpful in providing physiological microenvironments for tissues and organs. In this review, biomaterials, cells, and microscale technologies are described as essential components to construct OOC platforms. The latest developments in OOC platforms (e.g., liver, skeletal muscle, cardiac, cancer, lung, skin, bone, and brain) are then discussed as functional tools in simulating human physiology and metabolism. Future perspectives and major challenges in the development of OOC platforms toward accelerating clinical studies of drug discovery are finally highlighted.